G Nordmark

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi Autoantibodies to alpha-fodrin in primary Sjögren's syndrome and SLE detected by an in vitro transcription and translation assay
    G Nordmark
    Section of Rheumatology, Centre for Laboratory Medicine, University Hospital, Uppsala, Sweden
    Clin Exp Rheumatol 21:49-56. 2003
  2. ncbi Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome
    G Nordmark
    Section of Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Genes Immun 12:100-9. 2011
  3. ncbi Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome
    G Nordmark
    Section of Rheumatology, Uppsala University, Uppsala, Sweden
    Genes Immun 10:68-76. 2009
  4. ncbi Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus
    Gunnel Nordmark
    Department of Medical Sciences, Section of Rheumatology, University Hospital, Uppsala, Sweden
    Autoimmunity 38:531-40. 2005
  5. ncbi A polymorphic variant in the MHC2TA gene is not associated with systemic lupus erythematosus
    M V Prasad Linga-Reddy
    Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
    Tissue Antigens 70:412-4. 2007
  6. ncbi TSGA10 - A target for autoantibodies in autoimmune polyendocrine syndrome type 1 and systemic lupus erythematosus
    C J A Smith
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Scand J Immunol 73:147-53. 2011
  7. ncbi Increased carotid intima thickness and decreased media thickness in premenopausal women with systemic lupus erythematosus: an investigation by non-invasive high-frequency ultrasound
    D Leonard
    Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden
    Scand J Rheumatol 40:279-82. 2011
  8. ncbi Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus
    Snaevar Sigurdsson
    Molecular Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Hum Mol Genet 17:872-81. 2008
  9. ncbi A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5
    Snaevar Sigurdsson
    Molecular Medicine, Department of Medical Sciences, Uppsala University, SE 75185 Uppsala, Sweden
    Hum Mol Genet 17:2868-76. 2008
  10. ncbi Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus
    Snaevar Sigurdsson
    Molecular Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Am J Hum Genet 76:528-37. 2005

Collaborators

Detail Information

Publications13

  1. ncbi Autoantibodies to alpha-fodrin in primary Sjögren's syndrome and SLE detected by an in vitro transcription and translation assay
    G Nordmark
    Section of Rheumatology, Centre for Laboratory Medicine, University Hospital, Uppsala, Sweden
    Clin Exp Rheumatol 21:49-56. 2003
    ..To investigate the prevalence of alpha-fodrin autoantibodies in primary Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE) with and without secondary SS, using an in vitro transcription and translation assay (ITT)...
  2. ncbi Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome
    G Nordmark
    Section of Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Genes Immun 12:100-9. 2011
    ..EBF1, BLK and TNFSF4 are all involved in B-cell differentiation and activation, and we conclude that polymorphisms in several susceptibility genes in the immune system contribute to the pathogenesis of primary SS...
  3. ncbi Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome
    G Nordmark
    Section of Rheumatology, Uppsala University, Uppsala, Sweden
    Genes Immun 10:68-76. 2009
    ..43, whereas carriers of five risk alleles have an OR of 6.78. IRF5 and STAT4 are components of the type I IFN system, and our findings emphasize the importance of this system in the etiopathogenesis of primary SS...
  4. ncbi Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus
    Gunnel Nordmark
    Department of Medical Sciences, Section of Rheumatology, University Hospital, Uppsala, Sweden
    Autoimmunity 38:531-40. 2005
    ..Side effects were mild. We conclude that low dose DHEA treatment improves HRQOL with regard to mental well-being and sexuality and can be offered to women with SLE where mental distress and/or impaired sexuality constitutes a problem...
  5. ncbi A polymorphic variant in the MHC2TA gene is not associated with systemic lupus erythematosus
    M V Prasad Linga-Reddy
    Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
    Tissue Antigens 70:412-4. 2007
    ..We conclude that our data support neither allelic nor genotype association between the MHC2TA SNP and SLE...
  6. ncbi TSGA10 - A target for autoantibodies in autoimmune polyendocrine syndrome type 1 and systemic lupus erythematosus
    C J A Smith
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Scand J Immunol 73:147-53. 2011
    ..TSGA10 should be considered as an autoantigen in a subset of APS1 patients and also in a minority of SLE patients. No recognizable clinical phenotype could be found to correlate with positive autoantibody reactivity...
  7. ncbi Increased carotid intima thickness and decreased media thickness in premenopausal women with systemic lupus erythematosus: an investigation by non-invasive high-frequency ultrasound
    D Leonard
    Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden
    Scand J Rheumatol 40:279-82. 2011
    ....
  8. ncbi Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus
    Snaevar Sigurdsson
    Molecular Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Hum Mol Genet 17:872-81. 2008
    ..We have found that the same IRF5 allele also confers risk for inflammatory bowel diseases and multiple sclerosis, suggesting a general role for IRF5 in autoimmune diseases...
  9. ncbi A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5
    Snaevar Sigurdsson
    Molecular Medicine, Department of Medical Sciences, Uppsala University, SE 75185 Uppsala, Sweden
    Hum Mol Genet 17:2868-76. 2008
    ..82-fold risk of SLE with two independent risk alleles of the IRF5 (interferon regulatory factor 5) gene...
  10. ncbi Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus
    Snaevar Sigurdsson
    Molecular Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Am J Hum Genet 76:528-37. 2005
    ..TYK2 binds to the type I IFN receptor complex and IRF5 is a regulator of type I IFN gene expression. Thus, our results support a disease mechanism in SLE that involves key components of the type I IFN system...
  11. ncbi Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus
    Robert R Graham
    Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 104:6758-63. 2007
    ....
  12. ncbi Mechanisms of Disease: primary Sjögren's syndrome and the type I interferon system
    Gunnel Nordmark
    Uppsala University Hospital, Uppsala, Sweden
    Nat Clin Pract Rheumatol 2:262-9. 2006
    ..Several potential therapeutic targets for Sjögren's syndrome exist within the type I IFN system...